Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:584784.
doi: 10.1155/2011/584784. Epub 2011 May 10.

Pros and cons of focal therapy for localised prostate cancer

Affiliations

Pros and cons of focal therapy for localised prostate cancer

Luigi Mearini et al. Prostate Cancer. 2011.

Abstract

In prostate cancer, an interesting and intriguing option to overcome the risks of whole-gland treatment is focal therapy, with the aim of eradicating known cancer foci and reducing collateral damages to the structures essential for maintaining normal urinary and sexual function. Ablation of all known lesions would favorably alter the natural history of the cancer without impacting health-related quality of life and allows for safe retreatment with repeated focal therapy or whole-gland approaches if necessary. Our objective is to reassess the possibilities and criticisms of such procedure: the rationale for focal therapy and the enthusiasm come from the success of conservative approaches in treating other malignancies and in the high incidence of overtreatment introduced by prostate cancer screening programs. One of the challenges in applying such an approach to the treatment of prostate cancer is the multifocal nature of the disease and current difficulties in accurate tumor mapmaking.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer Journal for Clinicians. 2008;58(2):71–96. - PubMed
    1. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU International. 2002;90(2):162–173. - PubMed
    1. Whitmore WF., Jr. Localised prostatic cancer: management and detection issues. The Lancet. 1994;343(8908):1263–1267. - PubMed
    1. Berg CD, Andriole GL, Crawford ED, et al. Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine. 2009;360(13):1310–1319. - PMC - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine. 2009;360(13):1320–1328. - PubMed

LinkOut - more resources